



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/632136/2021

## European Medicines Agency decision P/0481/2021

of 3 December 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for marzeptacog alfa (activated) (EMEA-002270-PIP03-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**



# European Medicines Agency decision

P/0481/2021

of 3 December 2021

on the agreement of a paediatric investigation plan and on the granting of a deferral for marzeptacog alfa (activated) (EMA-002270-PIP03-20) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by Catalyst Biosciences, Inc. on 21 December 2020 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 October 2021, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for marzeptacog alfa (activated), powder for solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for marzeptacog alfa (activated), powder for solution for injection, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

This decision is addressed to Catalyst Biosciences, Inc., 611 Gateway Blvd., Suite 710, 94080 - South San Francisco, United States.



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/411184/2021  
Amsterdam, 15 October 2021

## Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-002270-PIP03-20

### Scope of the application

**Active substance(s):**

Marzeptacog alfa (activated)

**Condition(s):**

Treatment of haemophilia A

**Pharmaceutical form(s):**

Powder for solution for injection

**Route(s) of administration:**

Subcutaneous use

**Name/corporate name of the PIP applicant:**

Catalyst Biosciences, Inc.

### Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Catalyst Biosciences, Inc. submitted for agreement to the European Medicines Agency on 21 December 2020 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 26 January 2021.

Supplementary information was provided by the applicant on 9 July 2021. The applicant proposed modifications to the paediatric investigation plan.



## Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)**

# 1. Waiver

Not applicable

## 2. Paediatric investigation plan

### 2.1. Condition: Treatment of haemophilia A

#### 2.1.1. Indication(s) targeted by the PIP

Treatment of bleeding episodes in patients with congenital haemophilia A with inhibitors to Factor VIII

#### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

#### 2.1.3. Pharmaceutical form(s)

Powder for solution for injection

#### 2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable
Clinical studies	3	<b>Study 1 (MAA-304)</b> Randomised, open-label crossover study to evaluate the efficacy in terms of non-inferiority versus active treatment, and safety of MarzAA for the treatment of spontaneous or traumatic bleeding in adolescents from 12 years to less than 18 years of age (and adults) with congenital haemophilia A (HA) or haemophilia B (HB) with inhibitors. <b>Study 2 (MAA-202)</b> Open-label study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and effectiveness of MarzAA for the treatment of episodic bleeding in adolescents from 12 years to less than 18 years of age (and adults) with inherited bleeding disorders. <b>Study 3 (MAA-306)</b> Open-label two part study to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), effectiveness, and safety of MarzAA for the treatment of spontaneous or traumatic bleeding in children from birth to less than 12 years of age with congenital haemophilia A (HA) or haemophilia B (HB) with inhibitors.

Extrapolation, modelling and simulation studies	1	<b>Study 4 (MAA-POPPK-003)</b> Population pharmacokinetic (PopPK) modelling and simulation study to support paediatric dose finding.
Other studies	0	Not applicable
Other measures	0	Not applicable

### 3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2025
Deferral for one or more measures contained in the paediatric investigation plan:	Yes